← Back to Clinical Trials
Recruiting NCT06317324

NCT06317324 Compare the Prognostic Differences Between SBRT and Surgery for NSCLC Patients With Interlobular Fissure Invasion.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06317324
Status Recruiting
Phase
Sponsor Tianjin Medical University Cancer Institute and Hospital
Condition NSCLC
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2023-08-01
Primary Completion 2024-08-01

Trial Parameters

Condition NSCLC
Sponsor Tianjin Medical University Cancer Institute and Hospital
Study Type OBSERVATIONAL
Phase N/A
Enrollment 150
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-08-01
Completion 2024-08-01
Interventions
Different treatments

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The goal of this observational study is to compare the prognostic differences between SBRT and Surgery for NSCLC patients with interlobular fissure invasion. The main questions it aims to answer are: 1. Explore the survival differences. 2. Explore of the lung function changes before and after different treatments.

Eligibility Criteria

Inclusion Criteria: 1. Voluntarily participate and sign an informed consent form in writing; 2. Age 18 and above, regardless of gender; 3. Diagnosed as primary lung cancer through imaging/pathology, meeting the indications for SBRT and surgical treatment; 4. The clinical staging is cIB-IIIB stage (cT2-3N0M0), regardless of whether the staging is overestimated or underestimated as confirmed by pathology; 5. Imaging diagnosis of NSCLC patients with tumor invasion of interlobular pleura; 6. No serious abnormalities in the blood system, heart, lungs, liver, kidney function, or immune deficiency; 7. There are no restrictions on surgical methods, and both VATS and open chest surgery are acceptable; 8. Physical condition score ECOG level 0-2; 9. Expected survival time\>3 months. Exclusion Criteria: 1. Pathological confirmation of small cell lung cancer; 2. Non solitary lung cancer, non primary lung cancer, with distant metastasis; 3. Individuals with a history of severe lung or heart disease;

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology